Clopidogrel Global Market Report 2024

Clopidogrel is a medication used to prevent blood clots in conditions such as coronary artery disease, peripheral vascular disease, and cerebrovascular disease. It is particularly prescribed to reduce the risk of these events in individuals with acute coronary syndrome, recent heart attack, recent stroke, or a history of peripheral artery disease.

Clopidogrel is available in several formulations, 25mg, 75mg, and 300mg. Clopidogrel 25mg is specifically intended to inhibit blood clot formation and decrease the likelihood of heart attack and stroke. These formulations are distributed through various sales channels including direct sales and indirect sales, and are utilized in diverse settings such as hospitals, private clinics, retail pharmacies, online pharmacies, and others. They are used by a range of end-users including individuals affected by heart attack, strokes, peripheral vascular disease, coronary artery disease, cerebrovascular disease, among others.

The clopidogrel market research report is one of a series of new reports that provides clopidogrel market statistics, including clopidogrel industry global market size, regional shares, competitors with a clopidogrel market share, detailed clopidogrel market segments, market trends and opportunities, and any further data you may need to thrive in the clopidogrel industry. This clopidogrel market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The clopidogrel market size has grown rapidly in recent years. It will grow from $10.76 billion in 2023 to $11.87 billion in 2024 at a compound annual growth rate (CAGR) of 10.3%. The growth observed in the historical period can be attributed to several factors, heightened utilization of generic products, governmental healthcare initiatives, expanded adoption of clopidogrel in hospital settings, increased availability of clopidogrel in retail pharmacies, and rising usage of clopidogrel in emerging markets.

The clopidogrel market size is expected to see rapid growth in the next few years. It will grow to $17.78 billion in 2028 at a compound annual growth rate (CAGR) of 10.6%. The projected growth in the forecast period can be linked to several key factors, the increasing elderly population, heightened awareness regarding cardiovascular health, rising healthcare expenditure, greater emphasis on cardiovascular wellness, and growing demand for efficient cardiovascular treatments. Major trends anticipated in this period include advancements in technology, increased demand for cardiovascular medications, progress in medical research, growing demand for antiplatelet therapies, and the utilization of clopidogrel in combination with aspirin.

The clopidogrel market is set to expand due to the increasing prevalence of cardiovascular diseases. Cardiovascular diseases encompass various conditions affecting heart function and blood flow, exacerbated by factors such as population growth, aging, sedentary lifestyles, stress, and genetic predisposition. Clopidogrel plays a crucial role in preventing cardiovascular diseases by inhibiting platelet aggregation, thereby reducing the risk of clot formation. It is particularly effective in managing acute coronary syndromes, post-PCI care, stroke prevention, and peripheral arterial disease. For example, data from the Centers for Disease Control and Prevention indicates a slight increase in coronary heart disease prevalence among adults aged 18 and over from 4.6% in 2020 to 4.9% in 2021, highlighting the driving force behind the growth of the clopidogrel market.

The rising prevalence of peripheral artery diseases (PAD) is expected to further propel the clopidogrel market. PAD involves the narrowing or blockage of arteries outside the heart and brain, driven by factors such as smoking, aging, hypertension, and diabetes. Clopidogrel is essential in managing PAD by preventing platelet aggregation and reducing the risk of clot formation, thereby improving circulation and reducing symptoms associated with PAD. For instance, the Society for Cardiovascular Angiography and Interventions reports that PAD affects millions of Americans annually, with projections indicating a significant increase in prevalence by 2050. This trend underscores the increasing demand for clopidogrel in treating peripheral artery diseases.

Leading companies in the clopidogrel market are actively developing innovative medications such as Plavix (clopidogrel) to enhance efficacy, minimize adverse effects, improve patient adherence, and address concerns related to clopidogrel resistance. Plavix is pivotal in preventing thrombotic cardiovascular events by inhibiting platelet aggregation, reducing the incidence of heart attacks, strokes, and other clot-related complications in high-risk patients. For example, Sanofi S.A., a pharmaceutical company based in France, introduced Plavix with an expanded indication approved by the European Commission in February 2021. This approval allows Plavix to be used in combination with aspirin for a specified duration followed by long-term single antiplatelet therapy in patients who have experienced specific types of transient ischemic attacks or minor ischemic strokes within a defined timeframe.

Major companies operating in the clopidogrel market are Johnson & Johnson, F. Hoffmann-La Roche AG, Merck & Co. Inc., Bayer AG, Sanofi SA, Novartis AG, AstraZeneca Plc, Bristol-Myers Squibb, GlaxoSmithKline Plc, Takeda Pharmaceutical Company Limited, Eli Lilly & Company, Daiichi Sankyo Company Ltd., Sun Pharmaceutical Industries Ltd., Boehringer Ingelheim International GmbH, Aurobindo Pharma, Dr. Reddy's Laboratories Ltd., Torrent Pharmaceuticals GmbH, Cipla Inc., Apotex Inc., Intas Pharmaceuticals Ltd., Amneal Pharmaceuticals Inc., Lupin Limited, Glenmark Pharmaceuticals, Zydus Cadila Healthcare Ltd., Alkem Laboratories Ltd.

North America was the largest region in the clopidogrel market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the clopidogrel market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the clopidogrel market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The clopidogrel market consists sales of plavix, act clopidogrel, clopido grel, clopidogrel tablet and accel-clopidogrel. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.